CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 108 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $2,347,198 | -86.0% | 214,356 | -88.8% | 0.01% | -88.6% |
Q1 2023 | $16,760,738 | +65.4% | 1,922,103 | +18.9% | 0.11% | +142.6% |
Q4 2022 | $10,131,693 | +79.1% | 1,615,900 | 0.0% | 0.05% | +42.4% |
Q3 2022 | $5,656,000 | +21.7% | 1,615,900 | +2.6% | 0.03% | -54.2% |
Q2 2022 | $4,647,000 | +607.3% | 1,575,269 | +3015.6% | 0.07% | +1340.0% |
Q1 2018 | $657,000 | – | 50,560 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |